1. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation 
Kazuko Ino, Shigeo Fuji, Kinuko Tajima, Takashi Tanaka, Keiji Okinaka, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Naoyuki Katayama, Takahiro Fukuda 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 10, Pages (October 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Monitoring and change of peripheral blood WT1 levels before and after allo-HSCT.
Data indicate the WT1 levels before and 30 and 60 days after allo-HSCT. The upper row of text in each box indicates patient group based on WT1 levels (units: copies/µg RNA), and the lower row indicates the number of patients corresponding to each box.
NA indicates not available.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Cumulative incidence of relapse and overall survival before and after allo-HSCT according to MRD levels. Solid line, WT1 <50 copies/µg RNA; broken line, WT1 50 to 500 copies/µg RNA; dotted line, WT1 >500 copies/µg RNA. (A) and (B) before allo-HSCT, (C) and (D) day 30 after allo-HSCT, (E) and (F) day 60 after allo-HSCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
The prognosis of cases with elevated WT1. Of the 27 patients with hematological relapse, only 5 were alive at the end of the study. In contrast, all 13 patients with MRD but no hematological relapse survived. SCT indicates stem cell transplantation; GVL, graft versus leukemia.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions